Arvinas, Inc. (ARVN) Stock

Arvinas, Inc. (ARVN) is a Healthcare stock trading at $9.37 (as of 2026-08-21), with a market capitalization of $612.67M and a trailing P/E of 65.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Arvinas, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies designed to degrade disease-causing proteins, including PROTAC-based candidates such as Bavdegalutamide for metastatic castration-resistant prostate cancer and ARV-471 for metastatic ER-positive/HER2-negative breast cancer. It also develops ARV-766 for men with mCRPC and conducts programs in collaboration with major pharmaceutical partners.

Understand Arvinas, Inc.: how it makes money

Arvinas develops clinical-stage therapies that degrade disease-causing proteins using PROTACs, and it makes money through collaboration and license agreements and development milestone revenue rather than commercial product sales.

Because Arvinas is still a clinical-stage company with lead candidates in early trials, its profit model depends heavily on episodic partner revenue (collaborations, licenses, and development milestones), not recurring sales.

Business quality (Weak): The company is early in development, with operating losses and limited reported revenue, but its partnering activity and ongoing VERITAC-2 trial provide measurable milestones to watch.

Bull case

  • Partner-driven revenue sources are in focus: Identified revenue lines include a Vepdegestrant collaboration agreement with Pfizer and a Novartis license agreement, plus achievement of development milestone revenue.
  • VERITAC-2 trial momentum and comparative efficacy signal: VERITAC-2 includes 624 enrolled patients, with hazard ratio for progression-free survival versus fulvestrant (estrogen receptor 1-mutation population) provided as 0.57.

Bear case

  • Financial pressure typical of clinical-stage development: For the quarter ended 2026-03-31, revenue is 0.0B and operating margin is -409.0%.
  • Outcomes are not yet fully mature: Overall survival is described as immature, with 16.0% of deaths at the time of the progression-free survival analysis.
  • Dependence on trial progress for future economics: With lead candidates in phase I, future partner revenue and milestones are tied to clinical advancement, which can be uncertain.
Valuation — source: SEC EDGAR (first-party)
Price$9.37
Market Cap$612.67M
P/E Ratio65.9
Price / Book1.09
Price / Sales1.93
FCF Yield-34.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$262.60M
Net Margin-30.8%
Revenue Growth (YoY)1014.7%
EPS Growth (YoY)-410.7%
FCF Growth (YoY)-49.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.12 (distress)
Valuation vs Sector & Industry
Stock P/E65.9
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector203.1%
vs Industry283.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($85.74M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORandy Teel
Employees430
CountryUS
IPO Date2018-09-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Sensei Biotherapeutics, Inc. (SNSE)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • Crescent Biopharma, Inc. (CBIO)
  • CorMedix Inc. (CRMD)
  • Verastem, Inc. (VSTM)
  • Altimmune, Inc. (ALT)
  • Aquestive Therapeutics, Inc. (AQST)
  • Shattuck Labs, Inc. (STTK)
ARVN earnings history · ARVN institutional & insider holders · ARVN KPIs & operating metrics · ARVN financials · ARVN investor presentations & press releases · ARVN SEC filings · ARVN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.